Literature DB >> 16344051

Prevalence of Barrett's esophagus in the general population: an endoscopic study.

Jukka Ronkainen1, Pertti Aro, Tom Storskrubb, Sven-Erik Johansson, Tore Lind, Elisabeth Bolling-Sternevald, Michael Vieth, Manfred Stolte, Nicholas J Talley, Lars Agréus.   

Abstract

BACKGROUND & AIMS: Barrett's esophagus (BE) is associated with esophageal adenocarcinoma, the incidence of which has been increasing dramatically. The prevalence of BE in the general population is uncertain because upper endoscopy is required for diagnosis. This study aimed to determine the prevalence of BE and possible associated risk factors in an adult Swedish population.
METHODS: A random sample (n = 3000) of the adult population (n = 21,610) in 2 municipalities was surveyed using a validated gastrointestinal symptom questionnaire (response rate, 74%); a random subsample (n = 1000; mean age, 53.5 years; 51% female) underwent upper endoscopy. Endoscopic signs suggestive of columnar-lined esophagus (CLE) were defined as mucosal tongues or an upward shift of the squamocolumnar junction. BE was diagnosed when specialized intestinal metaplasia was detected histologically in suspected CLE.
RESULTS: BE was present in 16 subjects (1.6%; 95% confidence interval, 0.8-2.4): 5 with a long segment and 11 with a short segment. Overall, 40% reported reflux symptoms and 15.5% showed esophagitis; 103 (10%) had suspected CLE, and 12 (1.2%) had a visible segment > or = 2 cm. The prevalence of BE in those with reflux symptoms was 2.3% and in those without reflux symptoms was 1.2% (P = .18). In those with esophagitis, the prevalence was 2.6%; in those without, the prevalence was 1.4% (P = .32). Alcohol (P = .04) and smoking (P = .047) were independent risk factors for BE.
CONCLUSIONS: BE was found in 1.6% of the general Swedish population. Alcohol and smoking were significant risk factors.

Entities:  

Mesh:

Year:  2005        PMID: 16344051     DOI: 10.1053/j.gastro.2005.08.053

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  288 in total

1.  Barrett's esophagus before and after Roux-en-Y gastric bypass for severe obesity.

Authors:  Brandon Andrew; Joshua B Alley; Cristina E Aguilar; Robert D Fanelli
Journal:  Surg Endosc       Date:  2017-08-04       Impact factor: 4.584

Review 2.  The role of obesity in oesophageal cancer development.

Authors:  Elizabeth Long; Ian L P Beales
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

3.  Proximal and distal esophageal sensitivity is decreased in patients with Barrett's esophagus.

Authors:  Anne L Krarup; Søren S Olesen; Peter Funch-Jensen; Hans Gregersen; Asbjørn M Drewes
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

4.  The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model.

Authors:  Chung Yin Kong; Kevin J Nattinger; Tristan J Hayeck; Zehra B Omer; Y Claire Wang; Stuart J Spechler; Pamela M McMahon; G Scott Gazelle; Chin Hur
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-19       Impact factor: 4.254

Review 5.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 6.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

7.  Familial association in barrett esophagus.

Authors:  Yvonne Romero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-05

8.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katerina Dvorak; George S Watts; Lois Ramsey; Hana Holubec; Claire M Payne; Carol Bernstein; Gareth J Jenkins; Richard E Sampliner; Anil Prasad; Harinder S Garewal; Harris Bernstein
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

9.  Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.

Authors:  Aaron P Thrift; Lesley A Anderson; Liam J Murray; Michael B Cook; Nicholas J Shaheen; Joel H Rubenstein; Hashem B El-Serag; Thomas L Vaughan; Jennifer L Schneider; David C Whiteman; Douglas A Corley
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

Review 10.  Barrett esophagus: what a mouse model can teach us about human disease.

Authors:  Michael Quante; Julian A Abrams; Yoomi Lee; Timothy C Wang
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.